Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
He will be stationed at the company HQ in Bengaluru, India
CDSCO to fast-track trials and approval for COVID19 vaccine
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Five seats reserved for Wards of COVID warriors in central MBBS admission
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Subscribe To Our Newsletter & Stay Updated
